Navigation Links
Oncolytics Biotech(R) Inc. Announces Phase 3 Update Conference Call
Date:10/1/2009

CALGARY, Oct. 1 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), will host a conference call and webcast on Friday, October 2, 2009 at 6:30 a.m. MT (8:30 a.m. ET) to update investors on the Company's Phase 3 program for REOLYSIN(R).

To access the conference call by telephone, dial 1-416-644-3426 or 1-800-732-1073. A live audio webcast will also be available at the following link: http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2828320 or through the Company's website at www.oncolyticsbiotech.com. Please connect at least 15 minutes prior to the webcast to ensure adequate time for any software download that may be needed. A replay of the webcast will be available at www.oncolyticsbiotech.com and will also be available by telephone through October 9, 2009. To access the telephone replay, dial 1-416-640-1917 or 1-877-289-8525 and enter reservation number 4169017 followed by the number sign.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations as to the Phase 3 program for REOLYSIN, and the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.

SOURCE Oncolytics Biotech Inc.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial
2. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman Renshaw 11th Annual Healthcare Conference
3. Oncolytics Biotech(R) Inc. Announces Issuance of 32nd U.S. Patent
4. Oncolytics Biotech(R) Inc. Announces 2009 Second Quarter Results
5. Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)
6. Oncolytics Biotech(R) Inc. Completes Lyophilization Process for REOLYSIN(R)
7. Oncolytics Biotech(R) Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting
8. Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial
9. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
10. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
11. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... ... October 06, 2017 , ... ... providing advanced instruments and applications consulting for microscopy and surface analysis, Nanoscience ... application consulting, Nanoscience Analytical offers a broad range of contract analysis services ...
(Date:10/7/2017)... Mass. , Oct. 6, 2017  The ... work of three scientists, Jacques Dubochet, Joachim ... breakthrough developments in cryo-electron microscopy (cryo-EM) ... technology within the structural biology community. The winners ... Scientists can now routinely produce highly resolved, three-dimensional ...
(Date:10/6/2017)... ... 06, 2017 , ... On Tuesday, October 24th, ABC² (Accelerate ... first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker will be Dr. ... open to the public, but registration is required. , WHAT: ABC² Brain ...
(Date:10/5/2017)... Philadelphia, PA (PRWEB) , ... October 05, 2017 , ... ... of the newest frontiers in human health. Gut Love: You Are My Future, the ... offers an artist’s perspective as it explores the human condition through the lens of ...
Breaking Biology Technology:
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
Breaking Biology News(10 mins):